• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

更美好的生活:从康复者角度看有助于及阻碍进入和维持药物辅助治疗的因素

A Better Life: Factors that Help and Hinder Entry and Retention in MAT from the Perspective of People in Recovery.

作者信息

Baus Adam D, Carter Martha, Boyd Jennifer, McMullen Erin, Bennett Trey, Persily Alexandra, Davidov Danielle M, Lilly Christa

机构信息

West Virginia University School of Public Health; West Virginia Alliance for Creative Health Solutions, Inc.,

West Virginia Alliance for Creative Health Solutions, Inc.

出版信息

J Appalach Health. 2023 Apr 1;5(1):72-94. doi: 10.13023/jah.0501.06. eCollection 2023.

DOI:10.13023/jah.0501.06
PMID:38023116
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10629892/
Abstract

INTRODUCTION

Opioid addiction and opioid-related overdoses and deaths are serious public health problems nationally and in West Virginia, in particular. Medication-assisted treatment (MAT) is an effective yet underutilized treatment for opioid use disorder (OUD).

PURPOSE

Research examining factors that help individuals succeed in MAT has been conducted from provider and program perspectives, but little research has been conducted from the perspective of those in recovery.

METHODS

This study, co-developed with individuals in recovery, took place in West Virginia-based MAT programs using an exploratory sequential mixed methods approach. The survey was open February through August 2021. Data were analyzed late 2021 through mid 2022.

RESULTS

Respondents experienced many barriers to MAT entry and retention, including community bias / stigma, lack of affordable programming, and lack of transportation. Respondents sought MAT primarily for personal reasons, such as being tired of being sick, and tired of having to look for drugs every day. As one respondent shared,

IMPLICATIONS

Programs and policies should make it easy for individuals to enter treatment when ready, through affordable and accessible treatment options, reduced barriers to medications, focused outreach and education, individualized care, and reduced stigmatization.

摘要

引言

阿片类药物成瘾以及与阿片类药物相关的过量用药和死亡在全国范围内,尤其是在西弗吉尼亚州,都是严重的公共卫生问题。药物辅助治疗(MAT)是治疗阿片类药物使用障碍(OUD)的一种有效但未得到充分利用的治疗方法。

目的

从提供者和项目的角度开展了研究,探讨有助于个体在药物辅助治疗中取得成功的因素,但从康复者的角度进行的研究很少。

方法

本研究与康复者共同开展,在西弗吉尼亚州的药物辅助治疗项目中采用探索性序列混合方法。该调查于2021年2月至8月开放。数据于2021年末至2022年年中进行分析。

结果

受访者在进入和维持药物辅助治疗方面遇到了许多障碍,包括社区偏见/污名、缺乏负担得起的项目以及缺乏交通。受访者寻求药物辅助治疗主要是出于个人原因,比如厌倦生病,厌倦每天都要去找毒品。正如一位受访者所说,

启示

项目和政策应通过提供负担得起且可及的治疗选择、减少药物获取障碍、有针对性的外展和教育、个性化护理以及减少污名化,让个体在准备好时能够轻松进入治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b918/10629892/9f9a2eb1db90/jah-5-1-72f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b918/10629892/d37408ef3655/jah-5-1-72f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b918/10629892/9f9a2eb1db90/jah-5-1-72f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b918/10629892/d37408ef3655/jah-5-1-72f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b918/10629892/9f9a2eb1db90/jah-5-1-72f2.jpg

相似文献

1
A Better Life: Factors that Help and Hinder Entry and Retention in MAT from the Perspective of People in Recovery.更美好的生活:从康复者角度看有助于及阻碍进入和维持药物辅助治疗的因素
J Appalach Health. 2023 Apr 1;5(1):72-94. doi: 10.13023/jah.0501.06. eCollection 2023.
2
Access to MAT: Participants' Experiences With Transportation, Non-Emergency Transportation, and Telehealth.获取药物滥用治疗(MAT)的途径:参与者在交通、非紧急交通和远程医疗方面的体验。
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241233198. doi: 10.1177/21501319241233198.
3
Medication Assisted Treatment Program Policies: Opinions of People in Treatment.药物辅助治疗项目政策:治疗中人们的意见。
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231195606. doi: 10.1177/21501319231195606.
4
Perceived Ability to Treat Opioid Use Disorder in West Virginia.西弗吉尼亚州对阿片类药物使用障碍的治疗感知能力。
J Appalach Health. 2021 May 3;3(2):32-42. doi: 10.13023/jah.0302.04. eCollection 2021.
5
Review of medication-assisted treatment for opioid use disorder.阿片类药物使用障碍的药物辅助治疗综述。
J Osteopath Med. 2022 Mar 14;122(7):367-374. doi: 10.1515/jom-2021-0163.
6
Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.取消药物辅助治疗的事先授权:在医疗保险优势人群中对阿片类药物使用的影响及政策意义。
J Manag Care Spec Pharm. 2021 May;27(5):596-606. doi: 10.18553/jmcp.2021.27.5.596.
7
Cost-effectiveness of Treatments for Opioid Use Disorder.阿片类药物使用障碍治疗的成本效益。
JAMA Psychiatry. 2021 Jul 1;78(7):767-777. doi: 10.1001/jamapsychiatry.2021.0247.
8
Indiana community pharmacist preceptors' knowledge and perceptions of medication-assisted treatment.印第安纳州社区药剂师导师对药物辅助治疗的知识和看法。
J Am Pharm Assoc (2003). 2020 May-Jun;60(3S):S20-S28.e4. doi: 10.1016/j.japh.2020.01.001. Epub 2020 Feb 21.
9
Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails.推进监狱中阿片类物质使用障碍药物辅助治疗的实施与持续开展。
Health Justice. 2019 Dec 12;7(1):19. doi: 10.1186/s40352-019-0100-2.
10

引用本文的文献

1
"Trust and suspicion" Client and provider perspectives on the acceptability of medication for opioid use disorder among people who inject drugs in Kampala, Uganda.“信任与怀疑”:乌干达坎帕拉注射吸毒者对阿片类药物使用障碍药物可接受性的客户与提供者观点
Res Sq. 2025 Jun 17:rs.3.rs-6819472. doi: 10.21203/rs.3.rs-6819472/v1.
2
Exploring the Determinants of Treatment Completion Among Youth Who Received Medication-Assisted Treatment in the United States.探究美国接受药物辅助治疗的青少年完成治疗的决定因素。
Healthcare (Basel). 2025 Apr 2;13(7):798. doi: 10.3390/healthcare13070798.
3
Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial.

本文引用的文献

1
Perceived Ability to Treat Opioid Use Disorder in West Virginia.西弗吉尼亚州对阿片类药物使用障碍的治疗感知能力。
J Appalach Health. 2021 May 3;3(2):32-42. doi: 10.13023/jah.0302.04. eCollection 2021.
2
A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder.一项关于患者对物质使用障碍治疗的可及性、依从性、耻辱感和持续性方面的障碍及促进因素观点的系统文献综述。
Explor Res Clin Soc Pharm. 2021 Jun 4;2:100029. doi: 10.1016/j.rcsop.2021.100029. eCollection 2021 Jun.
3
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
护士保健经理实施基于办公室的成瘾治疗是否会延长初级保健中 OUD 治疗的持续时间?对 PROUD 随机对照试验的二次分析。
Drug Alcohol Depend. 2024 Dec 1;265:112497. doi: 10.1016/j.drugalcdep.2024.112497. Epub 2024 Nov 10.
4
Access to MAT: Participants' Experiences With Transportation, Non-Emergency Transportation, and Telehealth.获取药物滥用治疗(MAT)的途径:参与者在交通、非紧急交通和远程医疗方面的体验。
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241233198. doi: 10.1177/21501319241233198.
5
Medication Assisted Treatment Program Policies: Opinions of People in Treatment.药物辅助治疗项目政策:治疗中人们的意见。
J Prim Care Community Health. 2023 Jan-Dec;14:21501319231195606. doi: 10.1177/21501319231195606.
2019 年美国需要阿片类药物治疗的青少年和成年人中,阿片类药物使用障碍药物治疗的使用情况。
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
4
Stigmatization of medications for opioid use disorder in 12-step support groups and participant responses.12步支持小组中针对阿片类药物使用障碍药物的污名化及参与者的反应。
Subst Abus. 2022;43(1):415-424. doi: 10.1080/08897077.2021.1944957. Epub 2021 Jul 2.
5
Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge.度洛西汀治疗的慢性疼痛患者的人口统计学和临床特征与阿片类药物使用障碍的发生有关。
Drug Alcohol Depend. 2021 Jul 1;224:108703. doi: 10.1016/j.drugalcdep.2021.108703. Epub 2021 Apr 20.
6
Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.阿片类物质使用障碍药物治疗的障碍与促进因素:快速综述
J Gen Intern Med. 2020 Dec;35(Suppl 3):954-963. doi: 10.1007/s11606-020-06257-4. Epub 2020 Nov 3.
7
Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review.成人阿片类药物使用障碍药物维持治疗策略:快速证据综述。
J Addict Med. 2021;15(1):74-84. doi: 10.1097/ADM.0000000000000739.
8
Building Capacity for Medication Assisted Treatment in Rural Primary Care Practices: The IT MATTTRs Practice Team Training.在农村初级保健实践中建立药物辅助治疗能力:IT MATTTRs 实践团队培训。
J Prim Care Community Health. 2020 Jan-Dec;11:2150132720953723. doi: 10.1177/2150132720953723.
9
West Virginia's model of buprenorphine expansion: Preliminary results.西弗吉尼亚州丁丙诺啡扩展模式:初步结果。
J Subst Abuse Treat. 2020 Jan;108:40-47. doi: 10.1016/j.jsat.2019.05.005. Epub 2019 May 8.
10
Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?揭开丁丙诺啡滥用的神秘面纱:对药物转移的恐惧是否阻碍了阿片类药物危机的解决?
Subst Abus. 2019;40(2):148-153. doi: 10.1080/08897077.2019.1572052. Epub 2019 Apr 22.